Social Media Ideas for Zanvil Weinberger

<![CDATA[Solving Data Problems with Casual Human Biology: Q&A with Dr. Brent Richards]]>

Chutes & Ladders—Allogene swaps in CMO as new chief exec

After more than eight years at the helm of off-the-shelf CAR-T company Allogene Therapeutics, co-founder David Chang, M.D., Ph.D., is stepping down so that Zachary Roberts, M.D., P...

Allogene CEO to step down; Agios drug fails key test

David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approv...

<![CDATA[Inside the Expert Network Guiding TGN-S15 to Market]]>

Chutes & Ladders—Former FDA leader takes new biotech Turn

Stephen Hahn, M.D., who served as the commissioner of the FDA for just over a year during the first Trump administration, is taking his extensive regulatory expertise to Turn Thera...

How Zaynich will drive Wockhardt’s next phase of growth

After spending nearly Rs 6,800 crore and more than two decades, Wockhardt has achieved what no Indian pharmaceutical company has before: US FDA approval for a novel drug discovered...

Versiti: Jorge Di Paola, MD, to lead Versiti Blood Research Institute as Executive Vice President and Chief Scientific O...

MILWAUKEE — (June 8, 2026) — Versiti announced today that after an extensive national search, Jorge Di Paola, MD, an internationally recognized physician-scientist, hematology rese...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Utebzi and Capvaxive]]>

Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 11, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to th...

Incyte to Acquire Vega Therapeutics for Up-to-$2B, Growing Hematology Pipeline with Phase III VWD Candidate

Vega’s lead candidate VGA039 could, if approved, be the first subcutaneous prophylactic therapy with a more convenient once-monthly, self-administered dosing regimen for patients w...

"Truly evil" FDA rejection of gene therapy overturned after Trump official ousted

Gene therapy company UniQure had another FDA meeting after Vinay Prasad's exit.

‘Top-tier international executive’ Chen Lichtenstein to take the reins at Zim

Israeli carrier Zim has appointed Chen Lichtenstein (above) as its new president and CEO, to replace Eli Glickman. Mr Glickman resigned on 15 April, and Dr Lichtenstein will take u...

Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antit...

Alan G. Hinnebusch Receives $500,000 Gruber Genetics Prize for Breakthroughs in Integrated Stress Response

In a milestone moment for the field of molecular genetics, Alan G. Hinnebusch, PhD, a Distinguished Investigator at the National Institutes of Health, has been awarded the prestigi...

<![CDATA[Director of NIH Infectious Disease Institute Steps Down]]>

Fosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategy

In a recent interview with Fierce, Fosun Pharma co-president, Xinli Wang, M.D., Ph.D., detailed how the company leveraged two recent deals to quickly build up its portfolio in Alzh...

Servier Executive: ‘We Are Not Looking for Blockbusters, We’re Looking for Innovative Science’

Servier completed its acquisition of Day One Biopharmaceuticals and its buyout of Edgewise Therapeutics’ neuromuscular business is expected to close later this year. At the BIO Int...

BIO 2026: How a gut feeling transformed cancer treatment forever

Dr. Israel Lowy remembers the days when he and his oncology immunotherapy colleagues were assigned tables in the distant east wing of the American Society of Clinical Oncology conf...

Amyloidosis Continues To Fight Back